We investigated the role of adhesion molecules in skin involvement by acute myeloid leukemia (AML) using immunohistochemical analysis. Ten paired cases of skin and bone marrow biopsy specimens from patients with myeloid leukemia cutis (MLC) and 15 bone marrow biopsy specimens from patients without MLC were studied with antibodies directed against CD29, CD34, CD54, CD62-L, CD183, and cutaneous lymphocyte antigen (CLA). CLA was expressed in all cases of leukemia whereas CD54 was negative within blasts. CD62-L was expressed in 4 of 10 specimens of marrow infiltrates with MLC and 6 of 10 specimens of matching skin infiltrates; in marrows without MLC, only 2 of 15 were positive. CD29 was expressed in 1 of 10 marrow infiltrate specimens with MLC and 4 of 10 matching skin infiltrate specimens; in marrows without MLC, only 1 of 15 were positive. CD183 was expressed in 1 of 10 marrow infiltrate specimens with MLC and 4 of 10 matching skin infiltrate specimens; in marrows without MLC, CD183 was negative. The gain of CD62-L, CD29, and CD183 expression in bone marrow and skin infiltrates in leukemia cutis, relative to bone marrow infiltrates of cases without MLC, suggests a role for these markers in AML homing to skin.
We investigated the role of adhesion molecules in skin involvement by acute myeloid leukemia (AML) using immunohistochemical analysis. Ten paired cases of skin and bone marrow biopsy specimens from patients with myeloid leukemia cutis (MLC) and 15 bone marrow biopsy specimens from patients without MLC were studied with antibodies directed against CD29, CD34, CD54, CD62-L, CD183, and cutaneous lymphocyte antigen (CLA) . CLA was expressed in all cases of leukemia whereas CD54 was negative within blasts. CD62-L was expressed in 4 of 10 specimens of marrow infiltrates with MLC and 6 of 10 specimens of matching skin infiltrates; in marrows without MLC, only 2 of 15 were positive. CD29 was expressed in 1 of 10 marrow infiltrate specimens with MLC and 4 of 10 matching skin infiltrate specimens; in marrows without MLC, only 1 of 15 were positive. CD183 was expressed in 1 of 10 marrow infiltrate specimens with MLC and 4 of 10 matching skin infiltrate specimens; in marrows without MLC, CD183 was negative. The gain of CD62-L, CD29, and CD183 expression in bone marrow and skin infiltrates in leukemia cutis, relative to bone marrow infiltrates of cases without MLC, suggests a role for these markers in AML homing to skin.
Myeloid leukemia cutis (MLC) is a relatively infrequent complication of acute myeloid leukemia (AML). It occurs in less than 5% of systemic leukemia and has been associated with progression of disease and a worse outcome. [1] [2] [3] Patients with monocytic and myelomonocytic AML have been demonstrated to have a higher preponderance of MLC (up to 30%). 4 The literature also suggests an association between chromosome 8 aneuploidy and the frequency of MLC. 5 However, the parameters governing the occurrence of MLC are poorly understood.
Homing receptors, adhesion molecules, and chemokines have been shown to play an important role in lymphocyte trafficking in inflammatory conditions as well as in lymphomas. 6 For example, cutaneous lymphocyte antigen (CLA), a carbohydrate antigen related to sialyl Lewis x, is present on a subset (10%-15%) of memory T lymphocytes in the peripheral blood, tonsils, and lymph nodes, and is thought to be a specific homing molecule for skin. 7, 8 CLA expression has been reported in mycosis fungoides and other cutaneous lymphomas. 9,10 CD62-L (L-selectin) is expressed on lymphocytes, monocytes, and neutrophils. Expression of CD62-L has been documented in a large number of nodal lymphomas, as well as in skin lymphomas that involve the peripheral lymph nodes. 11 CD29 recognizes the b1 integrin subunit, which associates with alpha subunits to form various integrin receptors such as VLA-4 (a4b1). 6 CD54 (intercellular adhesion molecule 1 [ICAM-1]) is one of the ligands for aLb2 (LFA-1); it is usually present on endothelium but also can be expressed by lymphoma cells. 12, 13 CD183 (CXCR3) is a chemokine receptor that is also known to be a Th1 marker in T cells and Upon completion of this activity you will be able to: • discuss the factors important in lymphocyte homing. • list important homing/adhesion molecules in the skin and their ligands.
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Questions appear on p 307. Exam is located at www.ascp.org/ajcpcme. expressed by the epidermotropic cells of mycosis fungoides. 9 The expression of these molecules in myeloid leukemic cells has not been studied extensively.
Our aim was to study the role of these adhesion molecules/cytokines in the homing of myeloid leukemic cells to extramedullary sites in a small pilot study. Because skin is a common site of extramedullary involvement, we retrospectively examined 10 cases of MLC in which bone marrow involvement was established before, during, or after skin presentation. Concurrent bone marrow specimens were also studied. Both sets of specimens were stained with antibodies against CD29, CD34, CD54, CD62-L, CD183, and CLA. Bone marrow specimens of patients with AML but without skin involvement were also examined.
Materials and Methods

Case Selection
A total of 35 cases reviewed at Stanford University Medical Center (Stanford, CA) comprised the study and included 10 paired cases of MLC and systemic AML (20 cases overall) as well as 15 cases of AML without documented skin involvement. Clinical information was obtained by searching Stanford's clinical and pathology databases. Formalin-fixed paraffin-embedded skin biopsy specimens as well as Bouinfixed, decalcified, paraffin-embedded bone marrow biopsy specimens were used. H&E-stained sections, together with standard immunohistochemical studies performed at the time of diagnosis, were reviewed to confirm the original findings. Cytogenetic studies were performed on 24 of 25 cases ❚Table 1❚. All cases were selected before staining with antibodies directed against CD29, CD54, CD62-L, CD183, and CLA. Staining for CD34 was also performed if not done as part of the original analysis. This study was approved by Stanford's institutional review board.
Immunohistochemistry
Immunohistochemical studies for all markers were performed on conventional sections using a modified avidinbiotin peroxidase complex amplification and detection system ❚Table 2❚. Four-µm thick serial sections of tissue blocks were deparaffinized in xylene and rehydrated in alcohol. Endogenous peroxidase activity was quenched and antigen retrieval was then performed using previously published methods. 14 Staining for CD29, CD34, CD54, CD62-L, CD183, and CLA were primarily localized to the membrane and scored as follows: strongly positive, intense staining of at least 50% of blasts; weakly positive, staining of at least 10% but less than 50% of blasts; and negative, staining of less than 10% to no staining of blasts. A dot-like Golgi staining was also seen with CLA but not with the other stains. Positive scoring consisted of the sum of cases reported as either strongly or weakly positive. Positive internal controls were present in all cases (as described later), except for skin samples tested with CD62-L; the tonsil served as a positive external control for CD62-L. The epidermis served as negative controls for CD34, CD54, CD62-L, CD183, and CLA. The stratum spinosum served as a negative control for CD29.
❚Table 1❚ Summary of Clinicopathologic Characteristics of AML With and Without Leukemia Cutis, Including Clinical Information, WHO Classification, and Cytogenetics
Results
Clinical Features
The clinical characteristics of the patients in this study are listed in Table 1 . All of the patients with MLC were adults (age range, 24-77 years), of which 4 were men and 6 women. Of the patients without MLC, 13 were adults (age range, 23-83 years) and 2 were teenagers (13 and 16 years). Of these, 9 were male and 6 female patients. All leukemias were classified according to the 2008 World Health Organization classification. 15, 16 AML with myelodysplasia-related changes was the most common diagnosis in both categories, with 7 of 10 patients with MLC and 9 of 15 patients without MLC carrying this diagnosis. Many of these patients in both categories also had a history of myelodysplastic/myeloproliferative neoplasm. Chromosome 8 abnormalities were seen in only 1 case of MLC. In approximately one-half of the cases of patients with MLC, skin involvement by leukemia preceded bone marrow involvement. Extramedullary involvement outside the skin was uncommon (1/10 cases). All patients without documented skin involvement (cases 11-25, except cases 17 to 20 and case 24), were followed up for 6 months to 1 year, at which point the patient died. At the time of death, these patients had no skin disease. Cases 17 and 18 were followed up for 2 years, and case 19 was followed up for 5 years. None of these patients had skin disease at last follow-up. Cases 20 and 24 were lost to follow-up after 2 years but did not have skin disease at last follow-up.
Adhesion Molecule/Cytokine Expression in Normal Skin, Bone Marrow, and Tonsil
The expression pattern of these proteins in the constituents of normal skin and marrow is not well established, therefore we tested their expression in normal skin and bone marrow specimens performed as part of a staging workup for unrelated conditions, and tonsil excisional specimens. We found that CLA is normally expressed in small vessels in the skin, bone marrow, and tonsils, as well as in high endothelial venules in tonsils. CLA is also present in skin lymphocytes and in blasts, maturing myeloid cells, and neutrophils in the bone marrow. In blasts and maturing myeloid cells, membrane as well as Golgi staining can be seen. CD34 is present in vessels at all 3 sites, as well as in blasts in the bone marrow. CD54 is present in vessels in both the skin and the tonsil, and in plasma cells in the bone marrow; it is not present in blasts. CD183 is present only in lymphocytes in all 3 sites. CD62-L is present in a subset of T cells in the tonsil and in a subset of maturing myeloid cells in the bone marrow. It is essentially absent in the skin. CD29 is present in vessels in all 3 sites, in the basal keratinocytes of the skin, and in megakaryocytes and maturing myeloid cells in the bone marrow.
Adhesion Molecule/Cytokine Expression in Reactive Skin and Bone Marrow
To see if the expression patterns of adhesion molecules are different in reactive and neoplastic conditions, we tested biopsy specimens of reactive conditions involving the skin and bone marrow. For the skin, we examined neutrophil-rich specimens such as those associated with infection, leukocytoclastic vasculitis, and suppurative erythema nodosum. We tested similar specimens from the bone marrow, such as those related to marrow regeneration, recent cytokine therapy, and infection. We found that CLA was expressed as membrane and Golgi staining in immature myeloid precursors; a subset of neutrophils also showed Golgi staining. In the skin, CLA marked neutrophils but did not show significant Golgi staining; rare histiocytes were also highlighted. With CD-62L, megakaryocytes and neutrophils were highlighted, as were rare T cells. CD34 highlighted fewer than 5% of the cells in the marrow and did not highlight the inflammatory infiltrates in the skin. CD183 was largely negative in both skin and marrow; rare megakaryocytes and plasma cells were highlighted in the marrow, and rare histiocytes and some lymphocytes were highlighted in the skin. CD54 was also largely negative; rare plasma cells were highlighted in the bone marrow and rare histiocytes were marked in the skin. CD29 highlighted immature myeloid precursors and megakaryocytes in the bone marrow, but failed to highlight the inflammatory infiltrates in the skin.
Adhesion Molecule/Chemokine Expression in MLC
The expression patterns of CD29, CD34, CD54, CD62-L, CD183, and CLA are listed in ❚Table 3❚ and demonstrated in ❚Image 1❚, ❚Image 2❚, and ❚Image 3❚. We found that CLA was expressed ubiquitously in blasts in all cases tested, regardless of skin involvement. In contrast, CD54 was negative in all cases. CD62-L was expressed in 6 of 10 MLC cases and 4 of 10 matched bone marrow specimens; in cases without skin involvement, only 2 of 15 were positive. CD29 was present in 5 of 10 MLC cases but in only 1 of 10 matched bone marrow specimens; in cases without skin involvement, only 1 of 15 was positive. CD183 was expressed in 5 of 10 MLC cases but in only 1 of 10 matched bone marrow specimens; CD183 was not seen in any cases of patients without extramedullary disease. Finally, CD34 was expressed in 3 of 10 MLC cases and 5 of 10 matched bone marrow specimens; in cases without MLC, 8 of 15 expressed this marker. ❚Table 4❚ and ❚Table 5❚ demonstrate expression patterns of the markers in greater detail. Eight of 10 patients showed a phenotype discrepancy between skin lesions and matched bone marrow.
Discussion
In this pilot study, we wished to explore the possibility that cell surface molecules that are involved in homing of lymphocytes, granulocytes, and monocytes to sites of inflammation may also play a role in homing of leukemic cells to extramedullary sites. 17, 18 Cell surface homing molecules have been shown to be important in homing of T-cell lymphomas to skin. For example, Picker et al 8 found, among other things, that CLA was preferentially expressed in most skin T-cell lymphomas tested, but not in noncutaneous T-cell lymphomas. Similarly, Heald et al 11 found that CLA expression was increased in circulating malignant T cells in patients with erythrodermic mycosis fungoides relative to those with minimal patch stage disease. Our results demonstrate that CLA is uniformly expressed on AML blasts regardless of skin involvement. This suggests that, unlike T-lineage lymphoma cells, CLA may not be crucial in homing of myeloid leukemic cells to skin. 19 Although several studies have addressed CLA expression in granulocytes and its importance in adhesion to endothelial cells, no published reports have examined skin homing by CLA+ granulocytes, though that is assumed to be important. 19, 20 In contrast to CLA, we did find that the expression of CD62-L, CD29, and CD183 in bone marrow was increased in MLC compared with cases without MLC. In the case of CD62-L (L-selectin), this is an interesting finding, because CD62-L expression in lymphocytes is traditionally thought to play a role specifically in homing to peripheral lymph node high endothelial venules. 21, 22 However, CD62-L expression has been studied in myeloid leukemic cells, and has been found to be present in a small percentage of cases. 23 It is known that L-selectin ligands (MECA 79 antigens, including a specialized glycoform of CD34) are present in skin dermal microvasculature. 24 In addition, the number of lymphocytes bearing L-selectin in inflamed skin increases with an inflammatory stimulus in patients with atopic dermatitis. 25 Rare studies have also been performed with granulocyte homing in the analysis of ischemic/reperfusion injuries. 26 For example, Nwariaku et al 26 showed that CD62-L is partially responsible for the accumulation of granulocytes in postburn areas of skin and soft tissue in rabbits, but comparative analysis between sites was not performed to determine if CD62-L was -SKIN WP  1  2  0  5  4  2  LC-SKIN NEG  5  7  10  4  5  0  %P  50  30  0  60  50  100  LC-BM SP  10  0  3  0  1  0  8  LC-BM WP  1  2  0  3  1  2  LC-BM NEG  9  5  10  6  9  0  %P  10  50  0  40  10  100  BM SP  15  0  3  0  0  0  9  BM WP  1  5  0  2  0  6  BM NEG  14  7  15  13  15  0  %P  7  53  0  13  0  100 BM, bone marrow biopsy of patients without leukemia cutis; CLA, cutaneous lymphocyte antigen; LC-BM, leukemia cutis, bone marrow biopsy; LC-SKIN, leukemia cutis, skin biopsy; N, number of cases; NEG, negative, staining in <10% of blasts; SP, strong positive, staining in >50% of blasts; WP, weak positive, staining in >10% but <50% of blasts; %P, percentage of cases scored strong or weak positive. * Specimens were from skin and bone marrow of patients with and without leukemia cutis.
❚Image 1❚ Analysis of myeloid leukemia cutis with adhesion molecule markers. A, Sections show skin with a dense infiltrate of atypical cells within the dermis (H&E, ×10) . B, High-power view shows a nodule of atypical cells containing hyperchromatic, eccentrically placed nuclei, occasional prominent nucleoli, and pink cytoplasm (H&E, ×60). The lesional cells express cutaneous lymphocyte antigen (D, ×60), CD62L (E, ×60), and CD183 (F, ×60), and lack CD34 (C, ×60). 1 p/p n/p n/n n/n n/n p/n CD34, CD183 2 p/p n/n p/n n/n p/n p/n CD62-L, CD183 3 p/p n/n p/p n/n p/n p/n CD29, CD183 4 p/p n/p p/n n/n n/p n/n CD34, CD62-L, CD29 5 p/p n/p p/p n/n n/n p/n CD34, CD183 6 p/p p/p p/p n/n n/n p/p None 7 p/p p/p p/p n/n p/n n/n CD29 8 p/p n/n n/n n/n p/n n/n CD29 9 p/p n/n n/n n/n n/n n/n None 10 p/p p/n n/n n/n p/n n/n CD34, CD29 n, negative; p, positive (strong and weak positivity are added together vasculature. In addition, other ligands for CXCR3, such as mig and I-TAC, have both been shown to be synthesized and secreted by keratinocytes, and thought to play a role in lymphocyte chemotaxis in skin. Finally, CXCR3 has been reported to be present on the epidermotropic cells of mycosis fungoides. 9 Although the specific role of CXCR3 in leukemic cells in this context is not currently clear, the presence of its ligands in the skin and its expression in the epidermotropic cells of mycosis fungoides suggests a similar role in leukemic homing to skin. CD54, also known as ICAM-1, is the ligand for the integrin molecule LFA-1 (CD18/CD11a). 12, 30 It is widely expressed on nonhematopoietic cells such as vascular endothelium, select epithelial cells, and hematopoietic cells such as tissue macrophages, plasma cells, and dendritic cells. CD54 expression has been reported to be increased in leukemic blasts and other malignant cells. 13, 31 Interestingly, in our small cohort of patients, we could not document CD54 expression in blasts, but it was readily apparent on endothelial cells. This may be because of low levels of expression of CD54 on blasts that is beyond the sensitivity of detection on paraffinembedded tissues. 18 In addition, because it is known that the interactions between LFA-1 and ICAM-1 are important for the final steps of trafficking from the lumen of vessels into tissues, 12 and that ICAM-1 is ubiquitously expressed on vessels, LFA-1 expression on blasts and interaction with ICAM-1 expressed on vascular endothelium may be the key to egress of blasts from vessels into the surrounding tissues (rather than ICAM-1 expression on blasts). Both CD18 and CD11a have been documented to be highly expressed in AML blasts. 23 We are pursuing this analysis in a larger follow-up study.
Finally, while CD34 is widely known as a marker of primitive hematopoietic cells, it is also a sialomucin that promotes cell adhesiveness via its O-linked carbohydrate moiety and is thought to function as a ligand for L-selectin (as described before). 32 We have previously documented that CD34 expression is often diminished or lost in MLC compared with its expression in concurrent bone marrows, and have hypothesized that the loss may occur because of selection of a subgroup of CD34-negative blasts with increased propensity for extramedullary colonization or changes secondary to therapy. 16 Although CD62-L expression on blasts may facilitate migration to skin through interaction with CD34-expressing endothelial cells, we are unsure of the significance of CD34 loss on blasts in the context of extramedullary involvement. It is possible that loss of CD34 expression may facilitate egress of blasts from the marrow because of loss of interactions with marrow extracellular matrix, which is postulated to be important in retention of marrow precursors. 32 Loss of CD34 may be coupled with gain of other adhesion molecule expression (ie, CD62-L) which may also facilitate egress of blasts in a synergistic fashion.
particularly important for skin homing of granulocytes. Similar studies have not been performed for mature monocytes.
CD29 recognizes b1 integrins, and of these, the leukocyte integrin a4b1 is one of the most important. This integrin is involved in cell matrix interactions as well as cell-cell interactions. It is known to bind fibronectin as well as vascular cell adhesion molecule (VCAM-1). a4b1 is also known as very late antigen-4 (VLA-4), and is expressed in lymphocytes, monocytes, eosinophils, and neutrophils. This antigen has also been tested in normal blasts and myeloid leukemic blasts and found to be present in both scenarios. 23 It plays an important role in neutrophil migration to sites of inflammation, including inflamed joints, brain, and skin. 27, 28 Although it is not clear to us why the reactive neutrophilic infiltrates in skin failed to express CD29 (which highlights b1 integrins in all of its forms), the importance of CD29 in mediating neutrophilic migration at several sites might explain its increased expression in the cells of MLC.
CD183, also known as CXCR3, is a chemokine receptor thought to be important in skin homing of Th1 lymphocytes and in mediation of tissue rejection in transplantation. Major fractions of circulating memory CD4+ Th2 lymphocytes which express CCR4, another chemokine receptor, can also express CXCR3. 29 IP10, a chemokine partner of CD183/ CXCR3, is secreted by keratinocytes and expressed in dermal
